Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with
about a third of cases being genetic. Most of this genetic component is accounted for by …

The Montreal Cognitive Assessment (MoCA) is a cognitive screening instrument created with
the purpose of overcoming some of the insufficiencies of the Mini-Mental State Examination …

Oxidative stress has been shown to be a triggering event in the pathogenesis of Alzheimer's
disease (AD). However, little evidence exists on the role of oxidative imbalance in Mild …

Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic
frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN…

The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening
of milder forms of cognitive impairment, having surpassed the well-known limitations of the …

Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the
evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). …

Memory impairment is often present in frontotemporal dementia (FTD) as a result of an inefficient
use of learning strategies, sometimes leading to a misdiagnosis of Alzheimer's disease (…

Introduction Mononuclear phagocytes play a critical role during Alzheimer's disease (AD)
pathogenesis due to their contribution to innate immune responses and amyloid beta (Aβ) …

Recent studies show that most of the oxidative changes found in Alzheimer's disease (AD)
are already present in mild cognitive impairment (MCI) patients. The question arises as to …

The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and
encompass a long accrual of progressive biological (preclinical) and then clinical (prodromal) …